Shl Telemedicine Ltd. · SIX:SHLTN
Shl Telemedicine — H1 2024 Earnings Presentation
12 slides from Shl Telemedicine's earnings presentation, September 2024
Slide 1: SHL Telemedicine HY Results 2024 Presentation
SHL Telemedicine HY Results 2024 Presentation 1
Slide 2: Forward looking statements
Forward looking statements This presentation was prepared for the purpose of providing and presenting information in a summary only and cannot replace a review of the reports of SHL Telemedicine (hereinafter: "the Company"). Many of the statements included in this presentation, as well as oral state
Slide 3: SHL Telemedicine at a glance
SHL Telemedicine at a glance Telemedicine centers in Israel & Listed on Germany Significant strategic partners in the US market Nasdaq: SHLT SWX: SHLTN 1HY 2024 revenues interactions and data 3M $27.9M readings per year 30+ years of experience SHL is a leading provider and 24/7 telehealth monitoring
Slide 4: HY 2024 Overview Financial Data
HY 2024 Overview Financial Data(*) REVENUES Adjusted EBITDA(*) Operational CASH Flow $27.9M $ 0.5M $ (0.3)M CASH On HAND R&D Gross Expenses $20.3M $3.0M 30 June 2024 (*) Please see Supplemental Information at end of presentation for a reconciliation of Adjusted EBITDA and Adjusted EBIT to net profit
Slide 5: Germany
Germany: SHL is the market leader in Germany and operates 1HY2023 2HY2023 1HY2024 in a B2B model - managing and stabilizing chronic patients and saving costs for health insurers REVENUES(*) REVENUES(*) REVENUES The company has agreements with leading health insurers, covering about 30% of the German
Slide 6: USA
USA REVENUES $0.4M DTC plan: working on Leveraging the Tier1 Strategic customers relationships strengthen customer acquisition network of our reputation in support of the SmartHeart® direct- cost reduction cardiologists that is to-consumer move Adjusted already set up across EBITDA(*) the US $(2.2)M
Slide 7: Israel
Israel High contribution to the company's profitability and cash flow The leader in B2C Telemedicine Services 1HY2023 2HY2023 1HY2024 Sale of cardiac monitoring services to consumers: personal 12 Lead ECG devices for REVENUES(*) REVENUES(*) REVENUES transmission of remote medical data, 24/7 telemedi
Slide 8: Financials – P&L
Financials – P&L In USD million 1HY 2024 1HY 2023cc* (except per share amounts) Revenues for the period 27.9 28.4 Revenues by territories Germany 6.6 6.8 Israel 20.9 21.0 Rest of the World 0.4 0.6 Adjusted EBIT(**) (3.2) (3.2) Adjusted EBITDA(**) 0.5 0.3 Net loss (3.9) (2.2) EPS (Basic) attribute to
Slide 9: Financials – Balance sheet & Cash flow
Financials – Balance sheet & Cash flow In USD million 1HY 2024 1HY 2023 Cash and cash equivalents 10.9 10.4 Short term investments 9.4 19.0 Total cash and short-term investments 20.3 29.4 Short term bank debt 2.1 2.1 Long term bank debt 9.0 11.3 Total bank debt 11.1 13.4 Capital and reserves 151.4 1
Slide 10: Thank You
Thank You SHL Telemedicine 10
Slide 11: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted In the table below, HY 2023 results have been EBIT to net profit as required by the rules of the U.S. presented at HY 2023 exchange rates1. Management Securities Exchange Commission with respect to believes that this presentation
Slide 12: Supplement Information
Supplement Information Reconciliation of Adjusted EBITDA and Adjusted in USD million 1HY2023 EBIT to net profit as required by the rules of the U.S. 1HY2024 1HY2023 (CC1) Securities Exchange Commission with respect to non-GAAP financial measures (HY2022 results are Net profit (loss) (3.9) (2.1) (2.2